Bioheart, Inc.
13794 NW 4th Street
Suite 212
Sunrise,
FL 33325
United States - Map
Phone: 954-835-1500
Fax: 954-845-9976
Web Site: http://www.bioheartinc.com
| Bioheart, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of autologous cell therapies for the treatment of chronic and acute heart damage and peripheral vascular disease in the United States and Europe. Its lead product candidate is MyoCell, a clinical muscle-derived cell therapy designed to populate regions of scar tissue in a patients heart with autologous muscle cells for improving cardiac function in chronic heart failure patients. The companys products under development include Bioheart Acute Cell Therapy, an autologous adipose cell treatment for acute heart damage; TGI 1200 Adipose Tissue Processing System, an automated device for the rapid processing of patient derived fat tissue; and MyoCell SDF-1, an autologous cell therapy for the treatment of severe chronic damage to the heart and cells modified to express angiogenic factors. Its product candidates also include MyoCath, a disposable endoventricular catheter used for the delivery of biologic solutions to the myocardium; MyoCath II, a second generation disposable endoventricular catheter to provide multidirectional cell injection for the delivery of biologic solutions to the myocardium; and BioPace for the treatment of chronic abnormal heart rhythm. The company was founded in 1999 and is headquartered in Sunrise, Florida. |
|
| Key Statistics |
| |
| | Pay | Exercised | Dr. Howard J. Leonhardt Ph.D.,
Co-Founder, Chief Technology Officer, Chief Scientific Officer and Chairman of the Scientific Advisory Board |
$
150.00K | N/A | Mr. Scott R. Bromley , 47
VP of PR |
$
130.00K | N/A | Dr. Karl E. Groth Ph.D.,
Chairman, Chief Exec. Officer, Chairman of Governance & Nominating Committee, Member of Audit Committee and Member of Compensation Committee |
N/A
| N/A | Mr. Mark P. Borman , 54
Chief Financial Officer, Director and Member of Audit Committee |
N/A
| N/A | Ms. Peggy A. Farley ,
Chief Operating Officer, Independent Director, Chairman of Audit Committee, Member of Governance & Nominating Committee and Member of Compensation Committee |
N/A
| N/A |
|
|
|
Dollar amounts are as of
31-Dec-08
and compensation values are for the last fiscal
year ending on that date. "Pay" is salary, bonuses, etc. "Exercised" is the value of
options exercised during the fiscal year.
| |
|
1.54% Nasdaq 
0.20 (21.05%) 
Profile
